Ahmad et al presented their experience with four VADrefractory patients under autologous transplantation program who were salvaged with VAD plus thalidomide.
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These four patients, ranging from 45 and 69 years of age, two with a diagnosis of multiple myeloma (MM) type IgG, two type IgA, one patient in stage II and three patients in stage III, had been refractory to the administration of two and six cycles of VAD.
As a result, thalidomide was added to VAD, with doses up to 400 mg, resulting in two partial remissions (PR), one complete remission (CR) and a very good partial remission (VGPR) which allowed them to go on to a successful transplant.
We report our experience of a group of patients who have obtained good responses with the administration of thalidomide alone.
Our study shows six patients with MM, five women and one man (four IgG and two IgA), one patient in stage IA, two patients in stage IIA and three patients in stage IIIA (median age 48 years, range 44-67), who had not received any previous treatment and entered the transplantation program with VAD as first-line therapy. On average, they received 4.5 cycles (range 3-6). The attained response was disease progression in three cases and minor partial response (MPR) in other three. Only one patient received cyclophosphamide, idarubicine, and etoposide as secondline therapy, with no changes observed in the response. Owing to the bad response obtained, patients were started on thalidomide at 200 mg with escalation by 100 mg every 2 weeks and a maximum dose of 800 mg; mean dose was 350 mg (range 200-800 mg). Four patients were treated with dexamethasone 40 mg/week. The response was as follows: Two patients who had presented progression to VAD obtained CR and PR. Two other patients who had showed MPR presented VGPR. One patient who had presented PR to VAD obtained VGPR and another who had progression to first line reached CR.
The response was rapidly observed and the best response achieved with this treatment was reached in 80 days average, range 45-120.
Treatment was well tolerated and as thalidomide-related toxicity signs were low, it was not necessary to interrupt it. The patients who achieved partial or better responses continued in the transplant program.
Thalidomide is a new antimyeloma agent whose use is being researched at different disease stages. [2] [3] [4] [5] [6] In summary, according to our experience, we conclude that thalidomide alone or with corticoids may salvage VAD-refractory patients, improving the type of response and allowing the progress for an autologous transplant program. 
